GlassScriptPhysician profile
Elhamy Daoud Eskander
NPI 1528050473
$4,271.88
in general payments reported to CMS, 2019-2025
25 companies · $506 in 2025
The $506 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $96.21 · 2021: $1,407 · 2022: $510 · 2023: $477 · 2024: $438 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Education: $35.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.80 |
| Education | $35.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $781.08 | 2019-2025 | Opdivo |
| Beigene, LTD. | $525.00 | 2021 | |
| Amgen INC. | $320.76 | 2019-2025 | Imdelltra (Amg757) |
| Janssen Biotech, INC. | $281.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $280.49 | 2022-2025 | |
| Glaxosmithkline, LLC. | $259.92 | 2020-2024 | Ojjaara |
| Merck Sharp & Dohme LLC | $206.56 | 2023-2024 | Keytruda, Lynparza |
| Genentech USA, INC. | $200.86 | 2019 | |
| Incyte Corporation | $188.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $178.82 | 2019 | |
| Mirati Therapeutics, INC. | $162.12 | 2023 | Krazati |
| Genzyme Corporation | $123.30 | 2021 | |
| Eisai INC. | $114.91 | 2021 | |
| Kite Pharma, INC. | $112.14 | 2025 | Yescarta |
| Sumitomo Pharma America, INC. | $109.52 | 2023 | Orgovyx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $108.41 | 2021 | |
| Beigene USA, INC. | $103.36 | 2023 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $100.68 | 2024 | Libtayo |
| Novocure INC. | $39.99 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.02 | 2024 | |
| Caris Mpi, INC. | $18.67 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $14.68 | 2020 | |
| Myriad Genetic Laboratories, INC. | $13.87 | 2021 | |
| Clovis Oncology, INC. | $6.12 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elhamy Eskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.